NTLA - Intellia Therapeutics Inc logo

Intellia Therapeutics Inc

NTLA

Intellia Therapeutics develops CRISPR-based genome editing therapies, focusing on treatments for genetic disorders like hereditary angioedema and transthyretin amyloidosis. The company is in clinical trials for multiple therapies targeting serious diseases.

⚕️ Healthcare NASDAQ Listed 2016 $ USD
$1,000 invested 10 years ago →$708today

Score Overview

1 Year
Score
Net Growth3.08%
Net TrendGrew
Net Income Consistency—
Rev Growth-12.07%
Rev TrendShrank
Revenue Consistency—
5 Years
Score4.0
Net Growth-54.00%
Net Trend40%
Net Income Consistency—
Rev Growth80.03%
Rev Trend60%
Revenue Consistency—
10 Years
Score
Net Growth-10x
Net Trend20%
Net Income Consistency
Rev Growth261.10%
Rev Trend70%
Revenue Consistency
All Time
Score
Net Growth-10x
Net Trend20%
Net Income Consistency
Rev Growth261.10%
Rev Trend70%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Intellia Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 20 years of fundamentals. NTLA does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 12.03—
1 Year2025-09-29
$ 16.92-28.90%
5 Years2021-09-29
$ 137.56-91.25%
10 Years2016-09-29
$ 17.00-29.24%
All Time2016-05-06
$ 22.10-45.57%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 59M-$ 399M$ 437M
2025$ 67M-$ 412M$ 449M
2024$ 57M-$ 519M$ 601M
2023$ 36M-$ 481M$ 912M
2022$ 52M-$ 474M$ 1.19B
2021$ 33M-$ 259M$ 748M
2020$ 57M-$ 125M$ 597M
2019$ 43M-$ 99M$ 279M
2018$ 30M-$ 85M$ 314M
2017$ 26M-$ 67M$ 340M
IPO2016$ 16M-$ 31M$ 273M
NTLA - Intellia Therapeutics Inc logo

Intellia Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 57M to $ 67M and net income went from -$ 125M to -$ 412M. Revenue increased in 3 of those 5 years; net income in 2.

Across Intellia Therapeutics Inc's full reported history, from 2016 to 2025, revenue grew from $ 16M to $ 67M and net income went from -$ 31M to -$ 412M. Revenue increased in 70% of the years measured; net income in 20%.

Intellia Therapeutics Inc currently holds a 5-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.

Membership

Explore NTLA with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies